(Q43740775)

26 November 2017

title

A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest (English)

1 reference

26 November 2017

main subject

phase I clinical trial

0 references

1 reference

8

Vokes EE

1 reference

26 November 2017

2

Haraf DJ

1 reference

26 November 2017

George CM

1

1 reference

26 November 2017

Mauer AM

3

1 reference

26 November 2017

Krauss SA

4

1 reference

26 November 2017

Hoffman PC

5

1 reference

26 November 2017

Rudin CM

6

1 reference

26 November 2017

Szeto L

7

1 reference

26 November 2017

publication date

1 January 2001

1 reference

Investigational New Drugs

26 November 2017

published in

1 reference

26 November 2017

volume

19

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

303-310

1 reference

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma

26 November 2017

cites work

1 reference

12 December 2020

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug

1 reference

12 December 2020

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

12 December 2020

Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer

1 reference

12 December 2020

Oral platinum analogue JM216, a radiosensitizer in oxic murine cells

1 reference

12 December 2020

Enhanced radiation-induced cell killing by carboplatin in cells of repair-proficient and repair-deficient cell lines.

1 reference

12 December 2020

Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin

1 reference

12 December 2020

Preclinical antitumor activity of orally administered platinum (IV) complexes

1 reference

12 December 2020

Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients

1 reference

12 December 2020

Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.

1 reference

12 December 2020

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805

1 reference

12 December 2020

Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition

1 reference

12 December 2020

Radiosensitization by cisplatin of RIF1 tumour cells in vitro

1 reference

12 December 2020

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

12 December 2020

Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus

1 reference

12 December 2020

Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

1 reference

12 December 2020

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

1 reference

12 December 2020

A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration

1 reference

12 December 2020

Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks

1 reference

12 December 2020

Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors

1 reference

12 December 2020

Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus

1 reference

12 December 2020

Chemoradiation for locally advanced, unresectable NSCLC. New standard of care, emerging strategies

1 reference

12 December 2020

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation

1 reference

12 December 2020

Radiotherapy combined with low-dose cis-diammine dichloroplatinum (II) (CDDP) in inoperable nonmetastatic non-small cell lung cancer (NSCLC): a randomized three arm phase II study of the EORTC Lung Cancer and Radiotherapy Cooperative Groups

1 reference

12 December 2020

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Phase I study of oral JM216 given twice daily

1 reference

12 December 2020

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

1 reference

12 December 2020

A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1010653508700

1 reference

Dimensions Publication ID

26 November 2017

1015508958

0 references

1 reference